Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Gardasil Recall: Broken Glass Found in Syringes; polyDNA Recommends Gene-Eden-VIR, a Safe HPV Remedy
  • USA - English


News provided by

PolyDNA

Dec 27, 2013, 03:40 ET

Share this article

Share toX

Share this article

Share toX


Rochester, NY (PRWEB) December 27, 2013 -- polyDNA has learned that a total of 743,360 vials of the HPV vaccine, Gardasil have been recalled by Merck Pharmaceuticals because a small number of the vials may contain glass particles (1). polyDNA believes Merck’s recall is appropriate since the glass fragments are “small enough to go through a needle (1),” and may have entered the vaccine when something broke during the manufacturing process.

Perhaps, instead of constantly chanting the mantra ‘Gardasil is safe’, the CDC and FDA should be investigating and looking further into the findings of researchers like Dr. Lee. – Mike Evans, polyDNA

Post this

“People who may have received a contaminated vaccine do not need to worry, according to CDC. They may have a mild reaction like redness or swelling at the injection site, but nothing else more worrisome. The CDC does not think any delayed side effects will occur (1).”

polyDNA sees a similarity between the CDC’s reaction to the glass contamination and the FDA’s reaction to the vaccine’s contamination with foreign DNA. Just as the CDC downplayed any danger associated with glass fragments, the FDA downplayed any danger associated with the presence of foreign DNA (2).

The FDA says on its website in a page last updated on October 21, 2011 that "Since the early development of Gardasil, FDA and the manufacturer (Merck and Co., Inc.) have known that after purification of the vaccine, small quantities of residual recombinant HPV L1-specific DNA fragments remain in the vaccine. … The presence of DNA fragments is expected in Gardasil … these are not contaminants … The presence of these DNA fragments is expected, is not a risk to vaccine recipients, and is not a safety factor (2)."

Note the FDA’s claim that foreign DNA does not pose a risk.

Yet, the peer reviewed journal Advances in Bioscience and Biotechnology published a case report on November 26, 2012 that described a teenage girl who died after receiving the Gardasil vaccine (3). Sin Hang Lee with the Milford Molecular Laboratory in Connecticut confirmed the presence of HPV-16 L1 gene DNA in the girl’s postmortem blood and spleen tissue, and wrote “The significance of these HPV DNA fragments of a vaccine origin found in post-mortem materials is not clear and warrants further investigation (3).”

Dr. Lee suggested that the presence of HPV DNA fragments of vaccine origin provoke an exaggerated immune response. This is important to realize since the rate of anaphylaxis (a serious allergic reaction that may cause death) in girls receiving Gardasil is reportedly five to 20 times higher than any other school-based vaccination program. As an article published on Medscape noted “…researchers report that the rate of anaphylaxis after administration of the human papilloma virus (HPV) vaccine Gardasil (Merck), appears to be significantly higher than that reported for other vaccines administered in similar school-based programs.” The article was published on September 3, 2008 (4).

In addition, As of May 13, 2013, the Vaccine Adverse Event Reporting System (VAERS) had received 29,686 reports of adverse events following HPV vaccinations, including 136 reports of death, as well as 922 reports of disability, and 550 life-threatening adverse events, according to Medalerts.org, as of May 13, 2013. The information was accessed July 10. 9, 2013 (5)

The FDA and Merck admit that Gardasil contains foreign DNA fragments. However, the FDA asserts that these foreign DNA fragments "are not contaminants" and that they pose no risk to vaccine recipients like the glass shards discussed above.

“Clearly, there is evidence that Gardasil does, in fact, have HPV DNA fragments. Perhaps instead of constantly chanting the mantra ‘Gardasil is safe’, the CDC and FDA should be investigating and looking further into the findings of researchers like Dr. Lee.” – Mike Evans, polyDNA

People with infected with the latent HPV virus can ask their doctors about Gene-Eden-VIR, or they can go online to learn more. Gene-Eden-VIR is a safe, natural product that was proven to reduce HPV symptoms in a clinical study published in the peer reviewed, medical journal Pharmacology & Pharmacy, in a special edition on Advances in Antiviral Drugs on August 12, 2013.

The study showed that Gene-Eden-VIR reduced HPV symptoms and was safe and effective (6). “Up to 70% of those studied reported a decrease in viral symptoms (6).”
Each ingredient of Gene-Eden-VIR was chosen through a scientific approach. Scientists scanned thousands of scientific and medical papers published in various medical and scientific journals around the world to identify the safest, most effective natural ingredients that target the latent form of herpes (6).

Doctors can view the paper on Gene-Eden-VIR
here: http://gene-eden-kill-virus.com/PP_Gene-Eden-VIR-is-Antiviral.pdf

To learn more about Gene-Eden-VIR and HPV, visit http://gene-eden-kill-virus.com/HPV-Remedy.php. All orders of Gene-Eden-VIR are completely confidential, and no information is shared or sold to any third party. Privacy is assured.

Reference:

(1) HPV vaccine Gardasil voluntarily recalled due to glass shards in some vials. Published on December 23, 2013.
     http://www.cbsnews.com/news/hpv-vaccine-gardasil-voluntarily-recalled-due-to-glass-shards-in-some-vials/

(2) FDA Information on Gardasil – Presence of DNA Fragments Expected, No Safety Risk. Last updated on October 21, 2011.
http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm276859.htm

(3) Detection of human papillomavirus L1 gene DNA fragments in postmortem blood and spleen after Gardasil® vaccination—A case report. Published on November 26, 2012.
     http://file.scirp.org/Html/17-7300444_25840.htm

(4) Rate of Anaphylaxis After HPV Vaccine Higher Than Other Vaccines, Australians Report. Published on September 23, 2008.
     http://www.medscape.com/viewarticle/580017

(5) MedAlerts.org. HPV vaccine adverse event report to VAERS as of May 13, 2013. Accessed July 10. 9, 2013.

(6) Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published on August 12, 2013.
     http://gene-eden-kill-virus.com/PP_Gene-Eden-VIR-is-Antiviral.pdf

polyDNA is a biotechnology company that develops dietary supplements using the unique scientific method developed by Dr. Hanan Polansky, which is based on Computer Intuition.

In addition to his unique scientific method, Dr. Polansky published the highly acclaimed scientific discovery, called Microcompetition with Foreign DNA. The discovery explains how foreign DNA fragments, and specifically, DNA of latent viruses, cause most major diseases.

polyDNA developed Gene-Eden-VIR , an antiviral natural remedy that helps the immune system kill latent viruses.

Mike Davis, PolyDNA, http://gene-eden-kill-virus.com/, +1 5852509999, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.